The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer’s disease

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Psychopharmacology

• Publication date

  1997-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s002130050339PMID 9292621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease

  2005cited by this paper
• Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG

  2005cited by this paper
• Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging

  1996cited by this paper
• Studies on the role of K+, Cl- and Na+ ion permeabilities in the acetylcholine release enhancing effects of linopirdine (DuP 996) in rat cortical slices.

  1994cited by this paper
• Basal forebrain lesions in monkeys disrupt attention but not learning and memory [published erratum appears in J Neurosci 1995 Mar;15(3): following table of contents]

  1994cited by this paper
• SPECT images of technetium-99m-ethyl cysteinate dimer in cerebrovascular diseases: comparison with other cerebral perfusion tracers and PET.

  1994cited by this paper
• Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG.

  1993influential reference
• Comparison of technetium-99m-ECD to Xenon-133 SPECT in normal controls and in patients with mild to moderate regional cerebral blood flow abnormalities.

  1993cited by this paper
• Effects of the memory enhancer linopirdine (Dup 996) on cerebral glucose metabolism in naive and hypoxia-exposed rats.

  1993cited by this paper
• Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators.

  1993cited by this paper
• The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT.

  1992influential reference
• PET Imaging in Alzheimer's Disease

  1992cited by this paper
• Novel receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine, and serotonin release.

  1991cited by this paper
• Cerebral Pharmacodynamics of Physostigmine in Alzheimer's Disease Investigated Using Single-Photon Computerised Tomography

  1991influential reference
• Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography

  1991influential reference
• High-resolution PET studies in Alzheimer's disease.

  1991cited by this paper
• Cognition enhancement by the acetylcholine releaser DuP 996

  1990influential reference
• Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats.

  1990cited by this paper
• Regional cerebral blood flow and distribution of [99mTc]ethyl cysteinate dimer in nonhuman primates.

  1990cited by this paper
• Validity and Reliability of the Dementia Behavior Disturbance Scale

  1990influential reference
• Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease.

  1990influential reference
• Brain perfusion SPECT using an annular single crystal camera: initial clinical experience.

  1990cited by this paper
• Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease.

  1990influential reference
• DuP 996 (3,3‐bis(4‐pyrindinylmethyl)‐1‐phenylindolin‐2‐one) enhances the stimulus‐induced release of acetylcholine from rat brain in vitro and in vivo

  1990influential reference
• The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography.

  1989cited by this paper
• Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 2: Biodistribution and brain imaging in humans.

  1989cited by this paper
• Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects.

  1989cited by this paper
• Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine.

  1989influential reference
• Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 1: Pharmacology of technetium-99m ECD in nonhuman primates.

  1989cited by this paper
• EEG brain mapping in evaluating the time-course of the central action of DUP 996--a new acetylcholine releasing drug.

  1989cited by this paper
• Topographical distribution of neurochemical changes in Alzheimer's disease.

  1988cited by this paper
• Biochemical measurements in Alzheimer's disease reveal a necessity for improved neuroimaging techniques to study metabolism.

  1988cited by this paper
• The effect of acetazolamide on regional cerebral blood flow in normal human subjects as measured by single-photon emission computed tomography.

  1988cited by this paper
• Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET.

  1987cited by this paper
• [Cerebral glucose metabolism in presenile dementia of the Alzheimer type--follow-up of therapy with muscarinergic choline agonists].

  1986cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Biochemical evidence for cholinergic innervation of intracerebral blood vessels.

  1983cited by this paper
• Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey

  1983cited by this paper
• Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography.

  1981cited by this paper
• Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.

  1979cited by this paper
• AN ATLAS OF THE HUMAN BRAIN FOR COMPUTERIZED TOMOGRAPHY.

  1978cited by this paper
• Basal forebrain and hypothalamic connection to frontal and parietal cortex in the Rhesus monkey.

  1975cited by this paper
• Cerebral blood flow in dementia.

  1975cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Effects of Interventions on Cerebral Perfusion in the Alzheimer's Disease Spectrum: A Systematic Review.

  2022influential citation
• Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC50 Values in Aging and Alzheimer’s Disease, Using the Physiologically Based LeiCNS-PK3.0 Model

  2022cites this paper
• Effects of the Kv7 voltage‐activated potassium channel inhibitor linopirdine in rat models of haemorrhagic shock

  2018cites this paper
• 9 The Clinical Use of SPECT and PET Molecular Imaging in Alzheimer ’ s Disease

  2018cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Kv7 voltage-activated potassium channel inhibitors reduce fluid resuscitation requirements after hemorrhagic shock in rats

  2017cites this paper
• Development and Application of b-Amyloid Imaging Agents in Alzheimer’s Disease

  2016cites this paper
• Title: Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications Current Applicant: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• The Clinical Use of SPECT and PET Molecular Imaging in Alzheimer’s Disease

  2011cites this paper
• Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention

  2008cites this paper
• Voltage‐Gated Ion Channels

  2007cites this paper
• K(v)7 channels: function, pharmacology and channel modulators.

  2006cites this paper
• Guideline and Perspective

  2006cites this paper
• Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.

  2005cites this paper
• Psychopharmacology of Human Attention

  2005cites this paper
• Clinical PET

  2004cites this paper
• Dementia and Cerebrovascular Disease

  2004cites this paper
• A Meta-Analysis of Structural and Functional Brain Imaging in Dementia of the Alzheimer's Type: A Neuroimaging Profile

  2003cites this paper
• The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.

  2003cites this paper
• Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status: window of treatment.

  2002cites this paper
• A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials

  2002cites this paper
• PET imaging of brain acetylcholinesterase using [11C]CP‐126,998, a brain selective enzyme inhibitor

  2002cites this paper
• The acetylcholine release enhancer linopirdine induces Fos in neocortex of aged rats.

  2001cites this paper
• Future trends in the treatment of cognitive disorders.

  2001cites this paper
• Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

  2001cites this paper
• Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia.

  2001cites this paper
• Neuroimaging in alzheimer’s disease: Relevance for treatment

  2001influential citation
• Linopirdine (DUP 996): Cholinergic Treatment of Older Adults Using Successive and Non-successive Tests

  1999cites this paper
• Cognition enhancement strategies by ion channel modulation of neurotransmission.

  1999cites this paper
• 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: a correlative study.

  1999cites this paper
• acetylcholine release: potential therapies for Alzheimer's disease

  1998cites this paper
• Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease.

  1998cites this paper
• Ion channel modulators that enhance acetylcholine release: potential therapies for Alzheimer's disease.

  1998cites this paper